Dyax Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
203
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.5B
Dyax General Information
Description
Developer of biopharmaceuticals for oncology and inflammatory indications. The company offers drug discovery technology, known as phage display to identify antibody, small protein and peptide compounds for clinical development and provides chromatography separations systems and products that are used in laboratories and pharmaceutical manufacturing to separate molecules in liquid mixtures.
Contact Information
Corporate Office
- 55 Network Drive
- Burlington, MA 01803
- United States
Corporate Office
- 55 Network Drive
- Burlington, MA 01803
- United States
Dyax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 22-Jan-2016 | $6.5B | Completed | Generating Revenue | ||
| 11. PIPE | 02-Nov-2015 | Completed | Generating Revenue | |||
| 10. PIPE | 13-May-2013 | Completed | Generating Revenue | |||
| 9. PIPE | 01-Jan-2012 | Completed | Generating Revenue | |||
| 8. PIPE | 01-Jan-2009 | Completed | Generating Revenue | |||
| 7. PIPE | 01-Oct-2008 | Completed | Generating Revenue | |||
| 6. PIPE | 01-Aug-2006 | Completed | Generating Revenue | |||
| 5. PIPE | 14-Mar-2003 | Completed | Generating Revenue | |||
| 4. IPO | 15-Aug-2000 | $60M | $104M | Completed | Generating Revenue | |
| 3. Later Stage VC | 16-Nov-1998 | $31M | $44.5M | Completed | Startup |
Dyax Patents
Dyax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022076835-A1 | Methods and apparatuses for modeling adamts13 and von willebrand factor interactions | Inactive | 09-Oct-2020 | ||
| WO-2021202948-A2 | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome | Inactive | 04-Apr-2020 | ||
| WO-2021202948-A3 | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome | Inactive | 04-Apr-2020 | ||
| US-12528880-B2 | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack | Active | 13-Jan-2020 | ||
| US-20230192889-A1 | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack | Active | 13-Jan-2020 | C07K16/40 |
Dyax Signals
Dyax Former Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Baker Brothers Investments | Hedge Fund | Minority | ||
| BancBoston Capital | PE/Buyout | Minority | ||
| BancBoston Ventures | Venture Capital | Minority | ||
| Federated Investors and Affiliates | Corporation | Minority |
Dyax ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Dyax FAQs
-
When was Dyax founded?
Dyax was founded in 1995.
-
Where is Dyax headquartered?
Dyax is headquartered in Burlington, MA.
-
What is the size of Dyax?
Dyax has 203 total employees.
-
What industry is Dyax in?
Dyax’s primary industry is Drug Discovery.
-
Is Dyax a private or public company?
Dyax is a Private company.
-
What is the current valuation of Dyax?
The current valuation of Dyax is .
-
What is Dyax’s current revenue?
The current revenue for Dyax is .
-
How much funding has Dyax raised over time?
Dyax has raised $193M.
-
Who are Dyax’s investors?
Alta Partners, Baker Brothers Investments, BancBoston Capital, BancBoston Ventures, and Federated Investors and Affiliates are 5 of 27 investors who have invested in Dyax.
-
When was Dyax acquired?
Dyax was acquired on 22-Jan-2016.
-
Who acquired Dyax?
Dyax was acquired by Shire (Pharmaceuticals).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process